Rhumbline Advisers Amicus Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 412,106 shares of FOLD stock, worth $3.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
412,106
Previous 434,612 5.18%
Holding current value
$3.92 Million
Previous $4.31 Million 2.09%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$9.55 - $12.09 $214,932 - $272,097
-22,506 Reduced 5.18%
412,106 $4.4 Million
Q2 2024

Aug 01, 2024
BUY
$9.04 - $11.75 $176,198 - $229,019
19,491 Added 4.7%
434,612 $4.31 Million
Q1 2024

May 09, 2024
BUY
$11.43 - $14.24 $142,657 - $177,729
12,481 Added 3.1%
415,121 $4.89 Million
Q4 2023

Feb 08, 2024
SELL
$9.97 - $14.52 $134,395 - $195,729
-13,480 Reduced 3.24%
402,640 $5.71 Million
Q3 2023

Nov 09, 2023
BUY
$11.78 - $13.86 $16,162 - $19,015
1,372 Added 0.33%
416,120 $5.06 Million
Q2 2023

Aug 08, 2023
SELL
$10.72 - $13.3 $134,943 - $167,420
-12,588 Reduced 2.95%
414,748 $5.21 Million
Q1 2023

May 11, 2023
BUY
$10.91 - $13.54 $370,296 - $459,561
33,941 Added 8.63%
427,336 $4.74 Million
Q4 2022

Feb 14, 2023
BUY
$9.89 - $12.7 $207,393 - $266,319
20,970 Added 5.63%
393,395 $4.8 Million
Q3 2022

Nov 10, 2022
BUY
$9.82 - $12.75 $330,393 - $428,973
33,645 Added 9.93%
372,425 $3.89 Million
Q2 2022

Aug 11, 2022
BUY
$6.23 - $11.12 $329,405 - $587,958
52,874 Added 18.49%
338,780 $3.64 Million
Q1 2022

May 12, 2022
SELL
$7.89 - $12.48 $210,599 - $333,116
-26,692 Reduced 8.54%
285,906 $2.71 Million
Q4 2021

Feb 10, 2022
SELL
$9.82 - $12.44 $36,167 - $45,816
-3,683 Reduced 1.16%
312,598 $3.61 Million
Q3 2021

Nov 12, 2021
BUY
$8.74 - $11.84 $61,337 - $83,093
7,018 Added 2.27%
316,281 $3.02 Million
Q2 2021

Aug 05, 2021
BUY
$8.71 - $10.72 $21,217 - $26,113
2,436 Added 0.79%
309,263 $2.98 Million
Q1 2021

May 06, 2021
SELL
$9.2 - $23.86 $292,376 - $758,270
-31,780 Reduced 9.39%
306,827 $3.03 Million
Q4 2020

Feb 10, 2021
BUY
$13.47 - $24.89 $50,822 - $93,909
3,773 Added 1.13%
338,607 $7.82 Million
Q3 2020

Nov 12, 2020
SELL
$12.89 - $15.89 $980,439 - $1.21 Million
-76,062 Reduced 18.51%
334,834 $4.73 Million
Q2 2020

Aug 13, 2020
BUY
$8.86 - $15.69 $342,961 - $607,344
38,709 Added 10.4%
410,896 $6.2 Million
Q1 2020

May 06, 2020
BUY
$6.63 - $11.16 $100,444 - $169,074
15,150 Added 4.24%
372,187 $3.44 Million
Q4 2019

Feb 05, 2020
BUY
$7.48 - $10.75 $129,935 - $186,738
17,371 Added 5.11%
357,037 $3.48 Million
Q3 2019

Oct 23, 2019
BUY
$8.02 - $13.25 $158,723 - $262,230
19,791 Added 6.19%
339,666 $2.72 Million
Q2 2019

Aug 14, 2019
BUY
$10.96 - $14.4 $707,270 - $929,260
64,532 Added 25.27%
319,875 $3.99 Million
Q1 2019

May 01, 2019
BUY
$10.04 - $13.92 $30,009 - $41,606
2,989 Added 1.18%
255,343 $3.47 Million
Q4 2018

Jan 31, 2019
BUY
$8.38 - $13.44 $685,416 - $1.1 Million
81,792 Added 47.95%
252,354 $2.42 Million
Q3 2018

Nov 07, 2018
SELL
$11.6 - $16.54 $153,700 - $219,155
-13,250 Reduced 7.21%
170,562 $2.06 Million
Q2 2018

Aug 06, 2018
BUY
$13.13 - $17.09 $135,317 - $176,129
10,306 Added 5.94%
183,812 $2.87 Million
Q1 2018

May 02, 2018
BUY
$13.76 - $17.12 $210,184 - $261,508
15,275 Added 9.65%
173,506 $2.61 Million
Q4 2017

Feb 09, 2018
BUY
$12.51 - $16.24 $16,888 - $21,923
1,350 Added 0.86%
158,231 $2.28 Million
Q3 2017

Nov 06, 2017
BUY
$11.74 - $15.78 $1.84 Million - $2.48 Million
156,881
156,881 $2.37 Million

Others Institutions Holding FOLD

# of Institutions
313
Shares Held
314M
Call Options Held
516K
Put Options Held
833K
View Full List

About AMICUS THERAPEUTICS, INC.

FOLD Quotes by TradingView
  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.66B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email